Related Experiment Video

Updated: Sep 27, 2026

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia
06:01

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia

Published on: August 18, 2015

Antithrombotic drug treatment of pediatric patients with ischemic stroke

Ulrike Nowak-Göttl1, Ronald Sträeter, Guillaume Sébire

  • 1Department of Paediatric Haematology and Oncology, University Paediatric Hospital, University of Münster, Albert-Schweitzer-Strasse 3, 48149 Münster, Germany. leagottl@uni-muenster.de

Paediatric Drugs
|March 1, 2003
PubMed

Insights

Pediatric ischemic stroke lacks randomized trials, with treatments adapted from adult studies. Current management involves antiplatelet agents, heparins, warfarin, or alteplase, balancing efficacy against bleeding risk.

Area of Science:

  • Pediatric Neurology
  • Hematology
  • Cerebrovascular Disease

Background:

  • Stroke in children stems from diverse causes including congenital heart defects, sickle cell disease, infections, and metabolic disorders.
  • Cerebrovascular disease affects up to 80% of pediatric ischemic stroke cases, with hereditary prothrombotic factors implicated.
  • Limited research exists for pediatric stroke prevention and treatment, necessitating adaptation from adult protocols.

Purpose of the Study:

  • To review current treatment strategies for pediatric ischemic stroke.
  • To highlight the challenges in evidence-based management due to a lack of randomized clinical trials.
  • To discuss the use of various anticoagulants and antiplatelet agents in pediatric stroke.

Main Methods:

  • Review of existing literature on pediatric ischemic stroke.
  • Analysis of treatment approaches based on case series and case reports.
  • Examination of pharmacological interventions including antiplatelet agents, heparins, warfarin, and alteplase.

Main Results:

  • No randomized clinical trials exist for primary, short-term, or secondary prevention of pediatric ischemic stroke.
  • Treatment recommendations are primarily derived from adult stroke studies and individual patient data.
  • Pharmacological interventions like aspirin, low molecular weight heparin, warfarin, and alteplase are used, with careful consideration of bleeding risks.

Conclusions:

  • Evidence-based guidelines for pediatric ischemic stroke treatment are lacking.
  • Current management relies on extrapolated adult data and individual risk-benefit assessments.
  • Further research, including randomized trials, is crucial for optimizing pediatric stroke care.

More Related Videos

Prehospital Thrombolysis: A Manual from Berlin05:52

Prehospital Thrombolysis: A Manual from Berlin

Published on: November 26, 2013

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model09:42

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

Published on: June 4, 2021

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...